US Avascular Necrosis Market

ID: MRFR/MED/11470-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
US Avascular Necrosis Market Research Report: By Type (Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis), By Treatment (Nonsteroidal Anti-Inflammatory Drugs, Cholesterol Lowing Drugs, Osteoporosis Drugs, Blood Thinners, Others), By Diagnosis (Imaging, Biopsy, CT Scan, PET, X-Ray) and By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth & Industry Forecast 2025 To 2035
US Avascular Necrosis Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.09%
2024 Market Size$ 120 Million
2025 Market Size$ 127.31 Million
2035 Market Size$ 230 Million
Key Players
Amgen Inc
Bristol-Myers Squibb Company
Novartis AG
Pfizer Inc
Sanofi S.A.
Eli Lilly and Company
Trends
  • Rising Awareness and Early Diagnosis
  • Advancements in Treatment Modalities
  • Research and Development Initiatives
Opportunities
  • Rising Healthcare Expenditure
  • Increasing Incidence of Risk Factors
  • Technological Innovations in Imaging
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
      1. 4.1.1 Trauma Related Avascular Necrosis (AVN)
      2. 4.1.2 Non-Trauma Related Avascular Necrosis (AVN)
    2. 4.2 Food, Beverages & Nutrition, BY Treatment (USD Million)
      1. 4.2.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
      2. 4.2.2 Cholesterol Lowing Drugs
      3. 4.2.3 Osteoporosis Drugs
      4. 4.2.4 Blood Thinners
      5. 4.2.5 Others
    3. 4.3 Food, Beverages & Nutrition, BY Diagnosis (USD Million)
      1. 4.3.1 Imaging
      2. 4.3.2 Biopsy
      3. 4.3.3 CT Scan
      4. 4.3.4 PET
      5. 4.3.5 X-Ray
    4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
      1. 4.4.1 Hospital Pharmacies
      2. 4.4.2 Retail Pharmacies
      3. 4.4.3 Online Pharmacies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Amgen Inc (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bristol-Myers Squibb Company (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis AG (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer Inc (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Sanofi S.A. (FR)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Eli Lilly and Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck & Co., Inc. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 AstraZeneca PLC (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY TREATMENT
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY TREATMENT, 2024 TO 2035 (USD Million)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
      3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Avascular Necrosis Market Segmentation

US Avascular Necrosis Market By Type (USD Million, 2025-2035)

  • Trauma Related Avascular Necrosis (AVN)
  • Non-Trauma Related Avascular Necrosis (AVN)

US Avascular Necrosis Market By Treatment (USD Million, 2025-2035)

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
  • Cholesterol Lowing Drugs
  • Osteoporosis Drugs
  • Blood Thinners
  • Others

US Avascular Necrosis Market By Diagnosis (USD Million, 2025-2035)

  • Imaging
  • Biopsy
  • CT Scan
  • PET
  • X-Ray

US Avascular Necrosis Market By End User (USD Million, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.